Baxter Receives Tentative FDA Approvals For Ondansetron Injection In Vials And Premix Containers (RedNova)
DEERFIELD, Ill., June 15 /PRNewswire-FirstCall/ -- Baxter Healthcare Corporation today announced that it has received tentative approvals from the U.S.

Favrille Announces FDA Allowance of Investigational New Drug Application for FAV-201, a Patient-Specific Immunotherapy (RedNova)
SAN DIEGO, June 15 /PRNewswire-FirstCall/ -- Favrille, Inc.

FDA Grants Ceragenix's Request for Cerashield(TM) to be Reviewed as a Device (Business Wire via Yahoo! Finance)
DENVER----June 14, 2006--Ceragenix Pharmaceuticals, Inc. today announced that the FDA's Office of Combination Products in response to the Company's formal request has determined that Cerashield's primary mode of action is that of a device and it has been assigned to the FDA's Center for Devices and Radiologic Health for lead review.